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Abstract
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The association between chronic kidney disease (CKD) and cardiovascular disease (CVD) is well
established, and there is mounting evidence of inter-organ crosstalk that may accelerate
pathological processes and the progression of organ dysfunction in both systems. This process,
termed cardiorenal syndrome (CRS) by the Acute Dialysis Quality Initiative, is considered a major
health problem: patients with CKD and CVD are at much higher risk of mortality than patients
with either condition alone. To date, the majority of CRS research has focused on neurohormonal
mechanisms and hemodynamic alterations. However, mounting evidence suggests that
abnormalities in the normal pathophysiology of the bone-mineral axis, iron, and erythropoietin
play a role in accelerating CKD and CVD. The goal of this manuscript is to review the role and
interrelated effects of the bone-mineral axis and anemia in the pathogenesis of chronic CRS.
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Cardiorenal syndrome (CRS) is a group of diagnoses defined as disorders of the heart and
kidney whereby dysfunction in one organ induces or worsens dysfunction in the other. The
umbrella term and discrete subtypes (Box 1) were developed by the Acute Dialysis Quality
Initiative (ADQI) to emphasize the bidirectional pathways and to provide context for
identifying the complex pathophysiological interactions that occur in disorders that involve
both the heart and kidney.1
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Box 1
Discrete Subtypes of Cardiorenal Syndrome as Defined by the ADQI
Acute Cardiorenal Syndrome (Type 1): Acute worsening of cardiac function leading to kidney dysfunction
Chronic Cardiorenal Syndrome (Type 2): Chronic abnormalities in cardiac function leading to kidney
dysfunction
Acute Renocardiac Syndrome (Type 3): Acute worsening of kidney function causing cardiac dysfunction
Chronic Renocardiac Syndrome (Type 4): Chronic abnormalities in kidney function leading to cardiac
disease
Secondary Cardiorenal Syndromes (Type 5): Systemic conditions causing simultaneous dysfunction of the
heart and kidney

Abbreviation: ADQI, Acute Dialysis Quality Initiative
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Despite advances in treatment of both cardiovascular and kidney disease, CRS remains a
major health problem. Cardiovascular disease (CVD) is one of the most common causes of
death;2 In 2011, the US Centers for Disease Control and Prevention reported that nearly
25% of all deaths in the general population were due to the disease.3 Reduced kidney
function is associated with an increased risk for cardiovascular events and mortality
compared with that of the general population,4 with incrementally increased risk as
glomerular filtration rate declines.5,6 According to the US Renal Data System, CVD is the
most common cause of death in the setting of end-stage renal disease (ESRD).7 Of note,
individuals with stage 3 chronic kidney disease (CKD) are more likely to die of CVD than to
progress to ESRD.8 Furthermore, patients with combined cardiovascular and kidney disease
are at much higher risk of mortality than patients with either in isolation.9
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Since Lindner et al10 first described the association between ESRD and CVD, a number of
community-based studies, national databases, pooled analyses, and therapeutic intervention
trials have sought to validate the complex relationship between CKD and atherosclerotic
CVD.7,11–15 However, data specific to heart failure may be of greater value: a recent metaanalysis by Damman et al16 indicated that the prevalence of CKD in patients with heart
failure exceeds 30% and is associated with an odds ratio for all-cause mortality of 2.34 (95%
confidence interval [CI], 2.20–2.50).
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It appears that multiple mechanisms underlie CRS, and an extensive body of literature has
focused on neurohormonal mechanisms and hemodynamic alterations (Bock and
Gottlieb17). Given that abnormalities in iron, the bone-mineral axis, and anemia are frequent
complications of uremia (and that the management of CKD frequently involves
interventions directed at these parameters), the goal of this article is to review the potential
role of these factors in the pathogenesis and possible future prevention of chronic CRS
(types 2 and 4).

Biochemical abnormalities in CKD
Bone-mineral axis

Author Manuscript

Deterioration in mineral homeostasis is progressive as kidney function declines, causing
disruptions in serum and tissue concentrations of phosphate and calcium as well as changes
in circulating levels of hormones like parathyroid hormone (PTH), vitamin D metabolites
(calcidiol and calcitriol), and fibroblast growth factor 23 (FGF-23) (Figure 1). As early as
CKD stage 3, the kidneys show a reduced ability to appropriately excrete phosphate,
eventually resulting in hyperphosphatemia, which triggers elevations in PTH and FGF-23
concentrations. Further, impaired conversion of calcidiol to calcitriol reduces intestinal
calcium absorption and increases PTH levels. As the kidney is unable to respond adequately
to PTH, phosphaturia and calcium reabsorption are compromised. In addition, the kidney
does not respond to FGF-23 secreted by bone, further reducing phosphate excretion and
enhancing phosphate retention.18 Disruptions in the mineral and endocrine function
associated with CKD are vital in controlling bone modeling and remodeling; thus, bone
abnormalities are nearly ubiquitous in patients with dialysis-dependent CKD and
biochemically detectable in the majority of patients with CKD stages 3 to 5.19
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Iron
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Because excess iron is capable of generating free radicals that are damaging to lipid
membranes, proteins, and nucleic acids, circulating iron concentrations are tightly regulated.
Hepcidin is a key mediator, regulating iron stores by binding and inducing internalization
and degradation of ferroportin, an iron export protein. A genetic absence of hepcidin results
in unchecked iron absorption via the ferroportin channels and the clinical syndrome of
hemochromatosis.20 In chronic disease, hepcidin is produced at greater levels and reduces
the amount of iron absorbed from the gastrointestinal tract and also traps iron in the liver
and bone marrow macrophages, thereby restricting iron trafficking throughout the body,
particularly in the bone marrow. Hence, both intestinal iron absorption and iron release are
decreased; as such, circulating iron concentrations and iron availability to target tissues are
decreased as well.21 In patients receiving dialysis, iron homeostasis is disrupted further by
negative iron balance (due to blood losses from dialysis and repeated phlebotomy), depleted
iron stores (resulting from increased production of red blood cells during treatment with
erythropoiesis-stimulating agents), and impaired intestinal absorption of dietary iron (due to
relative achlorhydria).22
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Reduced synthesis of erythropoietin (EPO; 90% of which is produced in the kidneys, 10% in
liver and other organs), is considered an important cause of anemia in CKD. The main
stimulus for EPO production is renal hypoxia, but this mechanism is impaired in patients
with CKD.23 As kidney function declines, decreases in EPO are accompanied by a decrease
in available iron (as previously described), which further hinders erythropoiesis,
proliferation of erythroid precursors, and the production of EPO and EPO receptors.23
Finally, abnormalities in the availability of iron, excessive levels of inflammation,
disturbance in bone and mineral homeostasis, and other factors appear to decrease bone
marrow responsiveness to EPO, further exacerbating anemia as CKD progresses.24–27 Thus,
the anemia of CKD, including in those with chronic kidney failure, can be characterized by
elevated levels of hepcidin, impaired iron absorption and transport, reduced or
inappropriately low levels of and response to EPO, and (in patients treated with
hemodialysis) excess blood losses.
Relationship between the bone-mineral axis and iron
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Data on possible relations between the bone-mineral axis and iron are derived from
associations between hypophosphatemia and stimulated erythropoiesis in some
hematopoietic disorders28,29 as well as after intravenous (IV) iron infusion.30 Iron-induced
hypophosphatemia may result from increased cellular uptake of phosphate during
erythropoiesis, but renal phosphate wasting appears to be an important mechanism of ironinduced hypophosphatemia.31 Clinical data have shown that administering saccharated ferric
oxide32 or iron polymaltose33 results in impaired tubular phosphate handling
(reabsorption).32,33 In addition to renal phosphate loss, there is also evidence for inhibition
of renal 1α-hydroxylase activity and decreased 1,25-dihydroxyvitamin D concentrations. In
patients receiving dialysis or with earlier stages of CKD, effects of iron administration on
FGF-23 are inconsistent. In patients with non–dialysis-dependent CKD, ferric
carboxymaltose induces reduction in serum phosphate concentrations that persists for 3
months together with a significant decrease in FGF-23 concentrations (though other bone
metabolism parameters are unaffected).34 In patients treated with hemodialysis, IV
saccharated ferric oxide increases already elevated FGF-23 concentrations without inducing
hypophosphatemia and inappropriately low 1,25-dihydroxyvitamin D concentrations in the
absence of functioning kidney tissue. However, these findings have not been reported
consistently and could vary according to the iron preparation used.35,36 IV iron
administration may also result in transient PTH suppression, most likely through its effects
on FGF-23 and vitamin D by acting directly on the parathyroid.35,36
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In a recent study, Bacchetta et al37 explored the possibility of a direct role for vitamin D in
iron homeostasis. They found that supplementation with a single oral dose of vitamin D in
healthy volunteers was associated with a 34% reduction in circulating hepcidin within 24
hours. Based on these results, Bacchetta et al suggested that vitamin D is a key regulator of
the hepcidin-ferroportin axis, and highlighted vitamin D supplementation as a potential
means of managing anemia in patients with low vitamin D and/or CKD.
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Role of CKD-associated biochemical abnormalities in the pathogenesis of
cardiorenal syndrome
Role of Phosphorus and Calcium

Author Manuscript

The altered metabolism of phosphate, vitamin D3, and iron in CKD are likely to have
important contributing roles in the pathogenesis of impaired myocardial and vascular
function and the development of chronic CRS. Experimental evidence indicates that high
extracellular phosphate concentrations alter endothelial function38 and are toxic to vascular
endothelial cells. This results in apoptosis and subsequent exposure of underlying smooth
muscle cells to elevated levels of phosphate and stimulation of Pit-1 (a receptor encoded by
the SLC20A1 gene).39,40 The Pit-1 receptor signals vascular smooth muscle cells to undergo
transformation into osteoblastic-like cells, which secrete large quantities of calcium
hydroxyapatite crystals that ultimately result in vascular calcification in the subendothelial
and medial layers.38,41,42 Similarly, clinical studies have established that
hyperphosphatemia is strongly associated with vascular calcification and cardiovascular
mortality among individuals receiving dialysis.42 High serum phosphate levels also may
inhibit calcitriol synthesis, thus stimulating the renin-angiotensin-aldosterone system
(RAAS). Such stimulation induces vasoconstriction and salt/water retention, further
promoting arterial stiffening.43
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There is a strong association between vitamin D3 deficiency and cardiovascular
complications, including high blood pressure, vascular calcification, left ventricular
hypertrophy (LVH), hypertension, decreased myocardial contractility, and heart failure.43,44
In addition to their vascular effects, disturbed calcium and phosphorus may also directly
induce myocardial injury and dysfunction. In experimental models of uremia, a high
phosphorus diet combined with parathyroidectomy is associated with dramatic increases in
LVH, myocardial fibrosis, and myocyte diameter.45,46 An important role for myocardial
calcification similarly has been suggested for fetuin-A, a circulating protein synthesized in
the liver that acts as a potent inhibitor of tissue mineralization. In studies of the fetuin-A
knockout mouse, myocardial calcification occurs in the absence of significant vascular
calcification and is associated with significant changes in cardiac output, ventricular
stiffness, and myocardial collagen production and fibrosis.47
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Taken together, these and other data suggest that alterations in calcium and phosphorus
metabolism contribute to myocardial dysfunction and CRS in patients with reduced kidney
function. Although extensive clinical data are lacking on the role of calcium and phosphorus
in CRS, an elevation in the calcium-phosphorus product has been reported to be strongly
associated with LVH.48 Likewise, elevations in the calcium-phosphorus product or its
individual components have been described to be associated with increased risk of
cardiovascular mortality in the setting of dialysis-dependent CKD.49–51 Data on the
association between calcium or phosphorus concentration and heart failure outcomes are
limited. However, a handful of studies are consistent with an increased risk of heart failure
events among individuals with CKD and elevated calcium or phosphorus concentrations.51
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Given these associations, it seems likely that alterations in vitamin D, PTH, and FGF-23
homeostasis contribute to the development of chronic CRS. Nevertheless, the overall
evidence of a direct impact of vitamin D, PTH, and FGF-23 on endothelial and vascular
smooth muscle cells remains relatively sparse (although it recently was demonstrated that
FGF-23 promotes cardiomyocyte hypertrophy via a Klotho-independent pathway52). In
contrast, numerous experimental studies support the concept that this trio of hormones plays
a role in development of myocardial hypertrophy and fibrosis in the setting of CKD.
Administering vitamin D analogs, for example, markedly reduces LVH and ventricular
collagen accumulation in animal models of CKD,53 while there are similar increases in
fibrotic lesions and decreased expression of metalloproteinase inhibitors in vitamin D
receptor–knockout mice.54,55 With regard to PTH, a convincing body of experimental
evidence demonstrates that both surgical parathyroidectomy and medical parathyroidectomy
(using calcimimetics or activated vitamin D) inhibit myocardial fibrosis in disease models of
kidney disease.56–58 Administering FGF-23 also causes LVH, while treatment of uremic
animals with an FGF-receptor blocker attenuates LVH independent of blood pressure.52
Although the mechanism underlying this finding is uncertain, FGF-23 appears to
downregulate renal expression of angiotensin-converting enzyme 2, suggesting an intriguing
influence on the RAAS.59
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Clinical studies have confirmed that there are strong associations between this trio of
hormones and myocardial pathology. For example, vitamin D deficiency has been associated
with development of LVH in children with CKD.60 Similarly, high levels of PTH have been
described to be independently associated with LVH and with increased concentrations of
markers of cardiac damage and dysfunction (eg, troponin T and N-terminal pro–brain
natriuretic peptide [NT-proBNP]).61 Abnormalities in PTH and vitamin D also have been
reported to be associated with an increased risk of cardiovascular outcomes, including heart
failure.62 Several studies have demonstrated an association of FGF-23 concentrations with
the presence of LVH,63,64 and a graded association with the risk of hospitalization due to
heart failure.65
Role of Anemia and Iron Deficiency
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The prevalence of anemia may exceed 37% in patients with heart failure.66 The severity of
anemia has been associated with the degree of risk of ventricular dilation, hospitalization
due to heart failure, or overall mortality in patients with dialysis-dependent and earlier
stages of CKD;67,68 similarly, more severe anemia has been associated with an increase in
symptoms, reduced exercise capacity, and greater mortality in heart-failure populations.69
Although its role in the development of anemia may be primary, iron deficiency appears to
worsen heart failure independently of anemia: a recent study showed that health-related
quality of life among patients with heart failure was independently associated with iron
stores but not with the presence of anemia.70
Mechanisms underlying these associations remain incompletely understood; however, the
heart is rich in myoglobin, an iron-requiring protein essential in oxygen transport within the
cardiomyocyte. In vitro studies suggest that iron deficiency directly impairs myocyte
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mechanical function71 and that iron deficiency anemia induces LVH72 characterized by
myocyte hypertrophy and hypercellularity.73 Anemia also may exacerbate heart failure
through a series of downstream events in which tissue hypoxia and nitric oxide release cause
peripheral vasodilation and blood pressure decreases. This subsequently causes reduced
kidney function, increased renal vasoconstriction, and activation of the RAAS.74,75 In turn,
RAAS activation leads to fluid retention and release of NT-proBNP due to myocardial
stress, ultimately amplifying progressive kidney and cardiac failure.76
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Finally, iron administration may contribute to heart failure. Normally, <2% of circulating
and stored iron is unbound because of its tendency to catalyze oxidative stress reactions.
Lele and colleagues77 demonstrated that the heart releases catalytic iron, probably from
myoglobin in the setting of acute coronary syndrome. Akrawinthawong78 has shown that
free iron is released into the urine in acute kidney injury, which is followed by secretion of
neutrophil gelatinase–associated lipocalin. Although transient, IV iron infusions do elevate
blood levels of free iron,79 the consequences of which are unknown. In contrast, oral forms
of iron are absorbed via natural transport and binding mechanisms and do not result in
liberation of catalytic iron in the bloodstream.80 Thus, the absolute levels of circulating iron,
its form, and route of administration may potentially play important roles in cardiovascular
and renal physiology.
Role of EPO Deficiency and Resistance
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EPO, as well as its receptor (EPOR), is expressed in a number of nonerythropoietic tissues,
including cardiac myocytes. There is evidence supporting a role for EPO-EPOR signaling in
the modulation of physiologic responses to various types of nonerythropoietic tissue injury.
For example, EPO deficiency in mice has been shown to induce cardiac hypertrophy and
increase left ventricular dilatation,81 while exogenous administration of recombinant EPO
confers an acute cardioprotective effect during ischemia-reperfusion injury in rats.82 In
humans, several trials have demonstrated that EPO therapy of CKD-associated anemia can
induce regression of LVH.83–85 However, this effect has not been universal and may be
dependent on the severity of anemia.86 Moreover, multiple clinical trials have demonstrated
that exogenous EPO administration is associated with increased risks for the development of
heart failure, stroke, and other cardiovascular events. Such trials used high doses of EPO in
the setting of EPO resistance in an attempt to achieve a higher hemoglobin target,87 and
secondary analyses suggest that EPO in high doses is cardiotoxic. Thus, despite the potential
benefits, restricted EPO dosing may be a prudent approach. Whether hemoglobin levels
should also be limited in patients with CKD remains uncertain. The potential roles of the
factors mentioned in this section are summarized in Figure 2.
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Managing cardiorenal syndrome in clinical practice
Although nephrology and cardiology societies have developed thorough and up-to-date
guidelines for the management of CKD and CVD, there are no formal treatment
recommendations for the management of patients with CRS due to a lack of CRS-specific
trials. The overlapping interactions of the biochemical factors described in this review
illustrate the bidirectional nature of chronic CRS and emphasize the need for
multidisciplinary approaches in its treatment.
Am J Kidney Dis. Author manuscript; available in PMC 2016 August 01.
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There is evidence that diuretics and aldosterone antagonists are effective treatments in
patients with heart failure, as demonstrated by the DOSE (Diuretic Optimization Strategies
Evaluation) study88,89 and RALES (Randomized Aldactone Evaluation Study).90,91
However, use of these agents in patients with CKD is limited, the result of increased risk for
electrolyte disturbances such as hypokalemia or hyperkalemia.92,93
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A growing body of research suggests that hyperphosphatemia is a major promoter of
cardiovascular calcification in patients with CKD. Serum phosphate levels in this population
can be controlled with oral phosphate binders which, in theory, could improve
cardiovascular outcomes. Sevelamer, a nonabsorbable hydrogel, was the first aluminum- and
calcium-free phosphate binder for hyperphosphatemia management in dialysis patients;
however, evidence that sevelamer decreases calcification is limited. When compared to a
calcium-based phosphate binder, sevelamer reduced the progression of coronary and aortic
calcification in hemodialysis patients participating in the TTG (Treat to Goal) study.94
However, when compared to calcium acetate, sevelamer did significantly attenuate
progression of these conditions in two separate studies (the CARE-2 [Calcium Acetate
Renagel Evaluation 2] study and the BRiC [Phosphate Binder Impact on Bone Remodeling
and Coronary Calcification] study).95,96
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Despite a number of studies measuring surrogate outcomes for cardiovascular disease, to
date the mortality and cardiovascular benefits of phosphate reduction remain unproven.
Further, there is no solid evidence to support the superiority of a specific phosphate binder
in improving cardiovascular-related outcomes. To wit, the DCOR (Dialysis Clinical
Outcomes Revisited) trial, which compared the effects of calcium-based phosphate binders
and sevelamer on mortality, morbidity, and hospitalizations in hemodialysis patients, did not
find significant benefits to using sevelamer: over the course of 3 years, all-cause mortality
(17.7 versus 17.4 deaths/100 patient years, P = 0.9) and cardiovascular mortality (9.0 vs 8.2
deaths/100 patient years, P = 0.4) were very similar for sevelamer and calcium groups.97
Comparable trends were noted for first hospitalization and cause-specific multiple
hospitalizations.
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In regard to vitamin D, a recent post hoc analysis of the PRIMO (Paricalcitol Capsule
Benefits in Renal Failure-Induced Cardiac Morbidity) study demonstrated a lesser increase
of brain natriuretic peptide and left atrial index in patients with both diabetes and CKD
receiving an oral vitamin D analog (concomitantly with angiotensin-converting enzyme
inhibitors or angiotensin II receptor blockers) compared to patients taking placebo.98
However, the results for the primary outcome were negative, with no impact of paricalcitol
therapy on LVH.99 Furthermore, in a more recent study of individuals with CKD stages 3 to
5 and LVH at baseline, 1 μg of paricalcitol daily for 52 weeks had no effect on LV mass
index or volume, ejection fraction, or diastolic function compared with placebo.100
Similarly, the EVOLVE (Evaluation of Cinacalcet Hydrochloride Therapy to Lower
Cardiovascular Events) study of 3,883 patients receiving hemodialysis showed that
cinacalcet, a calcimimetic agent, had no significant effect on the combined cardiovascular
endpoint despite significant improvement in biochemical parameters of bone and mineral
metabolism.101 Interestingly, however, cinacalcet use was associated with an 18% reduction
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in the risk of hospitalization due to heart failure (95% CI, 0.58–0.99). To our knowledge, no
studies have specifically tested these therapies in individuals with CRS.
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Patients with chronic heart failure often are iron deficient, even before therapy with an ESA
results in gradual iron depletion. Thus, the use of IV iron before ESA therapy may help
reduce the amount of ESA needed. A small number of studies have been conducted in which
iron-deficient patients with chronic heart failure received IV iron. In the FAIR-HF (Ferinject
Assessment in Patients with Iron Deficiency and Chronic Heart Failure) study, IV iron
significantly improved symptoms of heart failure (odds ratio for improvement by one New
York Heart Association functional class, 2.40; 95% CI, 1.55–3.71; P < 0.001) and exercise
tolerance (6-minute walk test mean study treatment effect, 35 ± 8; P < 0.001) compared with
placebo. However, there was no significant difference in secondary clinical endpoints, such
as first hospitalization for cardiovascular causes or death (hazard ratio [HR], 0.61; 95% CI,
0.32–1.18; P = 0.14).102 The recent CONFIRM-HF (Ferric Carboxymaltose Evaluation on
Performance in Patients With Iron Deficiency in Combination With Chronic Heart Failure)
trial provides additional evidence of the potential benefits of iron therapy. Randomization to
ferric carboxymaltose was associated with significant improvements in the 6-minute walk
test, heart failure symptoms, and rate of hospitalization due to heart failure (HR, 0.39; 95%
CI, 0.19–0.82)103.
Conversely, data from TREAT (Trial to Reduce Cardiovascular Events with Aranesp®
Therapy) demonstrated that in non-dialysis patients with diabetes, CKD, and moderate
anemia, darbepoetin alfa did not decrease the risk of death or cardiovascular event,
congestive heart failure, nonfatal myocardial infarction, stroke, or hospitalization for
myocardial ischemia compared to placebo (HR, 1.05; 95% CI, 0.94–1.17; P = 0.41).104
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Available clinical evidence does not yet provide substantiated evidence for treating
abnormalities associated with mineral bone disease and anemia as a means of improving
outcomes of CRS. However, there are intriguing signals that merit further exploration of this
area.

Conclusion
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The Acute Dialysis Quality Initiative has defined CRS as disorders of the heart and kidney
in which dysfunction in one organ may cause dysfunction in the other. As reviewed here,
multiple lines of evidence suggest that in addition to the direct effects of uremia on
cardiovascular pathophysiology, secondary changes in bone and mineral metabolism, as
well as iron deficiency and anemia, have the potential to be important contributors to the
pathogenesis of chronic CRS. However, this connection remains underexplored. Relatively
few studies have investigated the potential for manipulating these factors to improve CRS
outcomes, and results to date have been equivocal at best. Given that patients with combined
CKD and CVD are at much higher risk of mortality than patients with either in isolation,
CRS is a major health concern. A better understanding of the roles and interrelated effects of
the biochemical factors discussed in this review, as well as more trials aimed at correcting
these factors in individuals with or at risk for CRS may help inform management and
treatment strategies for patients with CRS.
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Figure 1. Changes in bone and mineral metabolism in chronic kidney disease

Reduced functional kidney mass leads to phosphate retention and decreased activation of
vitamin D, thus resulting in hyperphosphatemia, reduced intestinal calcium absorption, and
hypocalcemia. Changes in phosphorous, calcium, and vitamin D, as well as decreased
kidney responsiveness, contribute to increased parathyroid hormone (PTH) and fibroblast
growth factor 23 (FGF-23) secretion.
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Figure 2. Anemia, bone, and mineral axis factors implicated in development of heart failure

Decreases in hemoglobin, erythropoietin, calcium, vitamin D, iron, and fetuin-A, as well as
increases in serum phosphorous, parathyroid hormone (PTH), and fibroblast growth factor
23 (FGF-23), may induce myocyte hypertrophy, mechanical dysfunction, and myocardial
fibrosis while simultaneously contributing to endothelial dysfunction, vascular stiffness, and
vascular calcification. These changes ultimately induce systolic and diastolic function, salt
and water retention, and the clinical syndrome of heart failure.
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